Me Therapeutics Holdings, Inc. · CSE:METX
Me Therapeutics — Investor Presentation (June 2026)
19 slides from Me Therapeutics's investor presentation, June 2026
Slide 1: Reprograming the immune response against cancer
Reprograming the immune response against cancer June 2026 METX: CSE | FSE:Q9T
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. This Presentation does not constitute an offer to sell or a soli
Slide 3: About Us
About Us ME Therapeutics is a biotechnology company involved in the discovery and development of novel therapeutics that engineer immune cells in vivo to directly recognize cancer cells and activate the body's immune response against cancer. Me Therapeutics | Investor Deck | 2026 3
Slide 4: Targeting the tumor microenvironment (TME)
Targeting the tumor microenvironment (Tme) IMMUNE CELL REPROGRAMING IN VIVO myeloid cells and Cancer associated fibroblasts block t cell responses • Myeloid cells (macrophages, myeloid derived suppressor cells) and Cancer associated fibroblasts (CAFs) are a major part of the tumor microenvironment (
Slide 5: The Landscape
The Landscape Our drug candidates target the immune system and not the cancer directly so they may be used in several cancer types. Breast cancer Pricing and target market (316,950 estimated cases in the U.S. in 2025)* Current Immuno-Oncology (IO) drugs (Keytruda, Opdivo) = ~ $190,000** Lung cancer
Slide 6: Innovative pipeline
Innovative pipeline • In vivo chimeric antigen receptor (CAR) program • CAR expression in T cells and myeloid cells • CD19/CD22 dual CAR for B cell leukemias (and autoimmune diseases) • CARs targeting solid tumors and fibrosis • Therapeutic mRNAs to modulate tumor microenvironment (TME) • Stimulate
Slide 7: Tumor targeting/reprogramming pipeline
Tumor targeting/reprogramming pipeline MOLECULE DISCOVERY PRECLINICAL PHASE 1 Cd19/cd22 dual in vivo car B cell tumor targeting sting mrna Tumor-specific immune stimulation In vivo car (tme target) In vivo CAR delivery targeting fibrosis Therapeutic cytokine mrna T cell stimulation in TME Me Therape
Slide 8: In vivo immune cell reprogramming
in vivo immune cell reprogramming • In vivo chimeric antigen receptor (CAR) delivery to myeloid cells and T cells • Engineering immune cells to recognize and destroy tumor cells or tumor supporting cells • Potential to improve solid tumor response • Myeloid cells can infiltrate some tumors better th
Slide 9: In vivo CAR program
In vivo car program CD19/CD22 in vivo CAR • CAR expression in both T cells and myeloid cells • dual antigen targeting approach for B-ALL and DLBCL • Novel CD22 nanobody binder being derisked in a Phase 1 clinical study • Nanobody based CAR smaller for more efficient delivery in vivo • CD19 targeting
Slide 10: Recent deals in the in vivo CAR space
Recent deals in the in vivo car space Date Acquirer / Investor Target / Partner Deal type Value / Terms Modality / Indication Relevance / Highlights In vivo CAR-T via targeted Platform + lead asset; Up to US $2.1 billion in LNP (tLNP) for B-cell 30 June 2025 AbbVie Capstan Therapeutics Acquisition a
Slide 11: In vivo pipeline
In vivo pipeline Therapeutic STING activating mRNA • STING is a key target for creating a hot TME (increasing immune cell recruitment, stimulating antigen presentation, overcoming resistance to checkpoint) • Several STING activators in clinical trials • So far all have been unsuccessful due to toxic
Slide 12: STING signaling compensates for low mutation burden
Sting signaling compensates for low mutation burden Suggests that activating STING could allow for an immune response in currently unresponsive cancers (low mutation burden) such as microsatellite stable metastatic colorectal cancer (a) TMB, STING, and Tex levels compared among low TMB clusters (One
Slide 13: Recent interest in STING
Recent interest in sting Gilead purchased TREX1 program from Sprint Biosciences in November 2025 for $14M upfront and up to $400M in biobucks • Preclinical stage • Small molecule • TREX1 is upstream of STING and enhances STING signaling by blocking degradation of excess DNA that stimulates STING Our
Slide 14: Active STING programs
Active sting programs Drug Name Sponsor Modality Route Mechanism of Action Dual-Action Targeted Agonist: Targets HER2 on tumor cells to deliver a STING agonist payload and binds Fcγ receptors XMT-2056 Mersana/GSK ADC (HER2-targeted) Systemic (IV) on immune cells (monocytes/DCs). This activates STING
Slide 15: Platform advantages
Platform advantages • mRNA platform adds significant value to company • Rapid design and testing of novel therapies based on cutting edge science • AI optimization of mRNA expression • mRNA design allows for targeted expression of protein of interest to modulate cancer or autoimmune conditions • Low
Slide 16: Scientific strategy
Scientific strategy • Deliver proprietary, AI optimized mRNA sequences encoding CARs or stimulatory proteins that are clinically derisked and/or scientifically validated but difficult to target with past approaches • Use derisked LNP delivery technology from world class partners to expedite developm
Slide 17: Development plan
Development plan • In vivo CAR proof of concept studies 2026 • Proof of concept NHP B cell depletion studies completed by LNP partners in 2026 • Non-GLP toxicology late 2026 • IND enabling studies – humanized mouse models • Manufacturing activities • Potential IND 2027 • Therapeutic mRNA program • I
Slide 18: Our Team
OUR TEAM Salim Dhanji | PhD, CEO, Director & Founder John Priatel | PhD, Director • Former director of preclinical research • Honorary Assistant Professor at at Qu Biologics University of British Columbia • Industry and academic expertise in cancer, • Expertise in lymphocyte biology, autoimmunity an
Slide 19: Thank You
Salim Dhanji, ph.d Chief Executive Officer Address 2665 East Mall Room 249 Vancouver, British Columbia , Canada V6T 1Z4 Thank You Contact Info Email: salim@metherapeutics.com Website metherapeutics.com
ME Therapeutics Holdings — Investor Presentation (June 2026) on 6ix